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Abstract
Acinetobacter baumannii primarily causes colonization, yet it can be an opportunistic pathogen associated with hospital-acquired 
infections. Many countries report rapid spread of carbapenem-resistant Acinetobacter baumannii (CRAb) which limits treatment 
options, with colistin frequently being the last line treatment option. The aim of our study was to evaluate a recently developed 
rapid method, namely the Rapid ResaPolymyxin test, for detection of colistin resistance (ColR) in Acinetobacter baumannii. This  
test was used for rapid screening of colistin resistance in a clinical setting where there is endemicity of CRAb isolates. A total of 
82 A. baumannii clinical isolates were included in the evaluation. The majority of them were resistant to carbapenems (75/82, 
91.5%). A total of 37 isolates (45.1%) were resistant to colistin, all being resistant to carbapenems. None of the ColR isolates 
carried the plasmid-mediated mcr-1 to -5 genes. The Rapid ResaPolymyxin NP test reached a 95.1% categorical agreement with 
results of reference broth microdilution method, with 93.3% sensitivity and specificity, and positive and negative predictive 
values being respectively at 92.3% and 97.7%. The Rapid ResaPolymyxin NP test performed well on our collection of clinical 
and surveillance CRAb isolates from the Central Slovenia region. The test is inexpensive and easy to integrate into laboratory 
workflow. The main value of the test is rapid categorization of susceptibility and resistance which has important implications with 
respect to the treatment strategy as well as the infection control measures.
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Introduction
Acinetobacter baumannii primarily causes colonization but
may be an opportunistic pathogen associated with hospital-
acquired infections, particularly among intensive care unit
(ICU) patients with prolonged hospitalizations and long-term
exposure to broad-spectrum antibiotics. ICUs are usually pri-
marily affected, but secondary spreads to general wards and
even long-term care facilities are also frequent [1].
While A. baumannii is intrinsically resistant to many anti-
biotic agents, it can also rapidly develop or acquire resistance
to virtually all antibiotics [2, 3]. Particularly worrisome is the
rapid spread of carbapenem-resistant A. baumannii (CRAb).
Overall, higher percentages of CRAb are reported from south-
eastern and southern Europe compared with northern and
western Europe [4]. Since 2014, invasive Acinetobacter sp.
isolates are included into systematic EARS-Net surveillance
following the 2012–2013 pilot phase. In 2017, the population-
weighted EU/EEA mean percentage for carbapenem resis-
tance was 33.4% (range 0.0–96.2%) and even more worrying,
the population-weighted EU/EEA mean percentage for com-
bined resistance to fluoroquinolones, aminoglycosides, and
carbapenems was 28.4% (range 0.0–84.3%) [5]. Treatment
options for infections caused by those multidrug-resistant
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bacteria are limited, with colistin being the most important
last-resort option. Data on colistin resistance among CRA
are scarce. In 2015 in Europe, resistance to colistin was ob-
served in 4.1% of carbapenem-resistant Acinetobacter sp. iso-
lates and 3.9% of carbapenem-susceptible invasive
Acinetobacter sp. isolates as reported to EARS-Net. As stated
in the report, these data have to be interpreted with caution as
the number of isolates included was relatively small and co-
listin susceptibility testing was not performed routinely. It
should also be noted that testing is technically challenging
and that testing procedure recommendations have recently
been changed [4–6]. Nevertheless, increasingly frequent re-
ports of colistin-resistant (ColR) CRAb are worrying [4].
In Slovenia, national data show a persistent decrease in
susceptibility to carbapenems in A. baumannii clinical iso-
lates, from 89.0% in 2011 to 66.7% in 2017 [7, 8]. Initially,
the main reasons for the spread of CRAb were transfers of
patients from foreign hospitals colonized and/or infected with
CRAb followed by a subsequent spread of these clones in
Slovenian hospitals. One of the most affected hospitals is the
tertiary teaching hospital UniversityMedical Centre Ljubljana
with CRAb prevalence among clinical isolates increasing
from 20.6% in 2011 to 62.0% in 2017 [9]. Until 2015, the
prevalence of ColR among clinical CRAb isolates in this hos-
pital was under 5%, but it increased to 7.8% in 2016, followed
by a significant spike in 2017 (17.5%) followed by a decrease
to 7.1% in 2018 ColR (Pirs M, unpublished data). The in-
crease in ColR prevalence was partially due to the implemen-
tation of new recommendations with regard to the susceptibil-
ity testing with the integration of the broth microdilution
(BMD) into routine practice [6], and mainly due to the noso-
comial spread of some ColR CRAb clones (Pirs M, unpub-
lished data).
Recently, the first rapid test for detection of colistin resis-
tance in Enterobacteriaceae, namely the Rapid PolymyxinNP
test, was developed [10]. This test, being based on detection of
glucose metabolization, cannot be applied to non-fermenters
such as A. baumannii. Therefore, and more recently, another
test was developed for rapid detection of colistin resistance in
Pseudomonas aeruginosa and A. baumannii, namely the
Rapid ResaPolymyxin NP test, based on the resazurin reagent
reduction which enables visual detection of viable bacteria as
observed by its color change [11]. The aim of our study was to
evaluate this new method for rapid screening of colistin resis-
tance from a collection of A. baumannii isolates recovered in a
clinical setting known to be endemic for CRAb, and among
which ColR CRAb may occur.
Materials and methods
Bacterial strains A total of 82 A. baumannii isolates were
recovered from patients at the tertiary teaching hospital
University Medical Centre Ljubljana (UMCL) in 2017 and
2018 and included in this study. Identification at the species
level was performed using the matrix-assisted laser desorption
ionization–time of flight (MALDI-TOF) mass spectrometer
(Microflex LT, Brucker Daltonics, Bremen, Germany).
Approximately half of the isolates (42/82, 51.2%) were from
clinical samples, the others being from rectal swab surveil-
lance samples (40/82, 48.8%).
Additionally, 20 Enterobacteriaceae isolates from our lab-
oratory strain collection were also tested using the Rapid
ResaPolymyxin NP test: 10 Escherichia coli (4 ColR), 6
Klebsiella pneumoniae (4 ColR), 4 Enterobacter cloacae (3
ColR), being all negative for the mcr-1 to -5 genes. Seven
mcr-1-positive E. coli isolates (MIC of colistin at 4 mg/L)
were also tested for the sake of comparison [12].
Control strains The colistin-susceptible E. coli ATCC 25922
and the colistin-resistant (mcr-1-positive) E. coli NCTC
13846 reference strains were used as positive and negative
controls, respectively.
Antimicrobial susceptibility testing Antimicrobial susceptibil-
ity to imipenem, aminoglycosides, trimethoprim/sulfamethox-
azole, and fluoroquinolones was determined using the disk
diffusion method. Susceptibility to colistin was determined
in duplicate using the in-house broth microdilution method
[6]. Colistin (sulfate salt; Sigma-Aldrich, France) was used
in a serial two-fold dilution ranging from 0.12 to 128 mg/L;
non-treated polystyrene 96-microtiter plates were used.
Results of susceptibility testing were interpreted according to
the valid EUCAST breakpoints (resistance being at > 2 mg/L)
[13].
Isolation of DNAGenomic DNAwas isolated using the Instant
Gene Matrix (Bio-Rad Laboratories, Hercules, USA) follow-
ing the manufacturer’s instructions.
Detection of mcr genes Detection of mcr-1, mcr-2, mcr-3,
mcr-4, and mcr-5 was performed on isolates with colistin
MIC ≥ 2 mg/L using the multiplex PCR as previously de-
scribed [14].
Carbapenemase gene detection CRAb were screened for the
blaOXA-23/-40/-58 carbapenemase genes with a multiplex PCR,
as previously described [15].
Rapid ResaPolymyxin NP test The test was performed as de-
scribed previously [10]. Briefly, we used the Mueller-Hinton
broth (MHB) (BBL, Becton Dickinson, Sparks, USA), with or
without colistin sulfate (sulfate salt; Sigma-Aldrich, France),
at a final concentration of 3.75mg/L. The bacterial suspension
was prepared at the 3.5 McFarland standard from overnight
bacterial colonies grown on a blood agar inoculated into two
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parallel wells, with and without colistin, in a non-treated poly-
styrene 96-microtiter plate (Sarstedt, Nümbrecht, Germany).
After 3 h of incubation at 35 °C in ambient air, 22 μL of the
10% resazurin dye PrestoBlue (Thermo Fisher Scientific,
Waltham, USA) was added to each well, and the contents of
each well were mixed by pipetting up and down. The plate
was again incubated at 35 °C in ambient air and visually
inspected every 15 min during the first hour, followed by
inspections at 2 and 3 h.
Negative controls using MHB, with and without colistin,
without the addition of a bacterial suspension were used in
every test batch to check for potential medium contamination.
Positive and negative control reference strains were also in-
cluded in every test batch.
The test was considered positive if the well contents were
purple/pink in color, indicating a viable polymyxin-resistant
isolate, and negative if the well contents were blue, indicating
the isolate was no longer viable, and thus polymyxin suscep-
tible. The result of the test for a bacterial isolate was valid if
the well without colistin remained blue. The test results were
valid if (i) both negative control wells without a bacterial
suspension remained blue (no MHB contamination), (ii) the
wells with a bacterial suspension without colistin turned from
blue to purple/pink (growth control), (iii) the colistin-
susceptible reference bacterial suspension in MHB with colis-
tin remained blue, and (iv) the colistin-resistant reference bac-
terial suspension in MHB with colistin turned from blue to
purple/pink.
To evaluate the Rapid ResaPolymyxin NP test perfor-
mance, MICs of colistin were determined with isolates recov-
ered from the same plate which was used for the Rapid
ResaPolymyxin NP test.
Results analysis The results obtained with the Rapid
ResaPolymyxin NP test were compared with the reference
BMD method. Categorical agreement (CA), very major errors
(VME, false-susceptible results), and major errors (ME, false-
resistant results) were calculated as described elsewhere [16, 17].
Results
A total of 82 A. baumannii clinical isolates were tested, among
which 37 (45.1%) were found resistant to colistin according to
MIC determinations (Fig. 1). None of the ColR isolates carried
anymcr-1 to -5 gene. Themajority ofA. baumannii isolates were
carbapenem resistant (75/82, 91.5%), and carried the blaOXA-23
(64/75, 85.3%) or blaOXA-40 (11/75, 14.7%) carbapenemase
genes. All ColR isolates were resistant to carbapenems and
fluoroquinolones, most of them being resistant to aminoglyco-
sides (24/37, 65% to gentamicin; 34/37, 8.1% to amikacin).
The Rapid ResaPolymyxin NP test reached a 95.1% categor-
ical agreement with results of BMD. It detected all but one ColR
A. baumannii with MIC at 32 mg/L (1.2% very major error).
Three isolates with colistin MICs 2 mg/L were false positives
(3.7% major error). The sensitivity of the Rapid ResaPolymyxin
NP test was 93.3% (CI 85.84–99.93%), the specificity 93.33%
(CI 81.73–98.60%), with a 92.31% positive predictive value (CI
80.06–97.29%) and a 97.67% negative predictive value (CI
85.85–99.66%). Overall, the performances of the Rapid
ResaPolymyxin NP test were excellent. They were even better
with Enterobacteriaceae isolates, since a 100% categorical
agreement and successful detection of both all ColR isolates
was obtained, regardless of the resistance mechanisms.
Discussion
We have evaluated the performance of the novel method for
rapid detection of colistin resistance among Acinetobacter
spp. using a collection of CRAb recovered in a single hospital
[10]. In the past 7 years, Slovenian prevalence of CRAb
Fig. 1 Distribution of colistin
MICs of Acinetobacter
baumannii isolates included in the
study
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among the total number of A. baumannii isolated increased
from 11.0% in 2011 to 33.3% in 2017 [7, 8]. Active infection
control measures help reducing the spread of CRAb on affect-
ed wards; however, continuing influx of colonized patients
particularly from foreign hospitals remains a problem. One
of the most affected hospitals is UMCL with ongoing spread
of multiple CRAb clones with two different carbapenemases
(OXA-23 or OXA-40) [9]. An increase in CRAb prevalence
led to an increased use of colistin, and it is challenging to face
out such phenomenon since detection methods are not always
adapted, being either inaccurate, fastidious, or time-consum-
ing. By using the Rapid ResaPolymyxin NP test, rapid and
accurate detection of colistin resistance was possible and very
few major or very major errors were observed. Three isolates
were false positives (3.7% ME), but in two cases, the patients
had ColR CRAb isolates from subsequent samples taken a
few days after the original isolate with a false positive Rapid
ResaPolymyxin NP test (in the third case, no subsequent sam-
ples were taken). Since the inoculum for the ResaPolymyxin
NP is higher than the inoculum used for BMD, it might be
speculated that resistant subpopulation undetected by the
BMD method could be detected by using the Rapid
ResaPolymyxin NP test. This test is inexpensive and easy to
integrate into laboratory workflow. Even though this test does
not precisely determine the MIC of colistin of the isolates
tested, its main value is rapid categorization between suscep-
tibility and resistance, which has important implications with
respect to the treatment strategy and/or rapid implementation
of isolation measures.
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